Clinical Trials

620 enrolled

Biliary Tract Neoplasms

NCT06746116 2026-04-16

DUoENDE

45 enrolled

Gynecologic

Endometrial Neoplasms

NCT07005128 2026-04-16

DeLLphi-312

330 enrolled

Small Cell Lung Carcinoma

NCT03778957 2026-04-15

EMERALD-1

724 enrolled

Carcinoma, Hepatocellular, Liver Neoplasms

NCT03528694 2026-04-14

POTOMAC

1,018 enrolled

Non-Muscle Invasive Bladder Neoplasms

NCT04960709 2026-04-14

VOLGA

712 enrolled

Urinary Bladder Neoplasms

NCT07195695 2026-04-08

Beamion LUNG-3: A Study to Test Whether Zongertinib Helps People With Surgically Removed, Non-small Cell Lung Cancer With HER2 Mutations Compared With Standard Treatment

400 enrolled

Carcinoma, Non-Small-Cell Lung

NCT05301842 2026-04-07

EMERALD-3

760 enrolled

Carcinoma, Hepatocellular, Liver Neoplasms

NCT07361497 2026-04-06

A Study to Evaluate Pumitamig Versus Durvalumab Following Concurrent Chemoradiation Therapy in Participants With Unresectable Stage III Non-small Cell Lung Cancer (NSCLC) (ROSETTA Lung-201)

850 enrolled

Carcinoma, Non-Small-Cell Lung

NCT06112379 2026-04-02

A Phase III Randomised Study to Evaluate Dato-DXd and Durvalumab for Neoadjuvant/Adjuvant Treatment of Triple-Negative or Hormone Receptor-low/HER2-negative Breast Cancer

1,902 enrolled

Breast

Breast Neoplasms

NCT06103864 2026-03-31

A Phase III Study of Dato-DXd With or Without Durvalumab Compared With Investigator's Choice of Chemotherapy in Combination With Pembrolizumab in Patients With PD-L1 Positive Locally Recurrent Inoperable or Metastatic Triple-negative Breast Cancer

625 enrolled

Breast

Breast Neoplasms, Neoplasm Metastasis

NCT06960577 2026-03-30

Perioperative Durvalumab With Neoadjuvant ddMVAC or Gemcitabine/Cisplatin in Patients With Muscle-invasive Bladder Cancer (NIAGARA-2)

150 enrolled

Urinary Bladder Neoplasms

NCT05771480 2026-03-25

TOURMALINE

142 enrolled

Biliary Tract Neoplasms

NCT06992609 2026-03-25

ALBORAN

70 enrolled

Phase 3 Enrolling by invitation

Small Cell Lung Carcinoma

NCT05303532 2026-03-24

ROSY-D

214 enrolled

Tumor-Agnostic

Neoplasms

NCT06282575 2026-03-24

Efficacy and Safety of Zanidatamab With Standard-of-care Therapy Against Standard-of-care Therapy for Advanced HER2-positive Biliary Tract Cancer

286 enrolled

Biliary Tract Neoplasms, Gallbladder Neoplasms, Cholangiocarcinoma

NCT06890598 2026-03-24

SUNRAY-02

700 enrolled

Carcinoma, Non-Small-Cell Lung

NCT03298451 2026-03-20

HIMALAYA

1,324 enrolled 31 charts 2 FDA

Carcinoma, Hepatocellular

NCT03875235 2026-03-19

TOPAZ-1

810 enrolled 24 charts 2 FDA

Biliary Tract Neoplasms

NCT05629585 2026-03-18

A Study of Dato-DXd With or Without Durvalumab Versus Investigator's Choice of Therapy in Patients With Stage I-III Triple-negative Breast Cancer Without Pathological Complete Response Following Neoadjuvant Therapy (TROPION-Breast03)

1,174 enrolled

Breast

Breast Neoplasms

NCT07221253 2026-03-17

AB02

1,100 enrolled

Biliary Tract Neoplasms, Gallbladder Neoplasms, Recurrence

NCT03164616 2026-03-13

POSEIDON

1,186 enrolled 26 charts 2 FDA

Non Small Cell Lung Cancer NSCLC

NCT03732677 2026-03-13

NIAGARA

1,063 enrolled 15 charts 3 FDA

Urinary Bladder Neoplasms

NCT05687266 2026-03-13

AVANZAR

1,350 enrolled

Carcinoma, Non-Small-Cell Lung

NCT03003962 2026-03-11

Study of Durvalumab Alone or Chemotherapy for Patients With Advanced Non Small-Cell Lung Cancer (PEARL)

669 enrolled 54 charts

Non Small Cell Lung Carcinoma NSCLC

NCT05943106 2026-03-11

PATAPSCO

100 enrolled

Non-Muscle Invasive Bladder Neoplasms

NCT03847428 2026-03-06

EMERALD-2

908 enrolled

Carcinoma, Hepatocellular, Liver Neoplasms

NCT05170204 2026-03-06

HORIZON 1

71 enrolled

Carcinoma, Non-Small-Cell Lung

NCT02453282 2026-03-02

MYSTIC

1,118 enrolled 40 charts

Carcinoma, Non-Small-Cell Lung

NCT03706690 2026-03-02

PACIFIC-5

407 enrolled 22 charts

Carcinoma, Non-Small-Cell Lung

NCT05211895 2026-02-23

PACIFIC-8

860 enrolled

Carcinoma, Non-Small-Cell Lung

NCT05883644 2026-02-18

SIERRA

111 enrolled

Liver Neoplasms

NCT03682068 2026-02-03

NILE

1,246 enrolled

Urinary Bladder Neoplasms

NCT04550260 2026-01-29

KUNLUN

640 enrolled

Esophageal Squamous Cell Carcinoma

NCT02516241 2026-01-28

Study of MEDI4736 (Durvalumab) With or Without Tremelimumab Versus Standard of Care Chemotherapy in Urothelial Cancer

1,126 enrolled 52 charts

Urothelial Cancer

NCT07229625 2026-01-28

A Phase III Study of SHR-8068 in Combination With Adebrelimab and Platinum-Containing Chemotherapy Versus Durvalumab in Combination With Platinum-Containing Chemotherapy as First-line Treatment for Advanced Biliary Tract Cancer (BTC)

604 enrolled

Advanced Biliary Tract Cancer

NCT05221840 2026-01-27

PACIFIC-9

1,051 enrolled

Carcinoma, Non-Small-Cell Lung

NCT03833154 2026-01-26

PACIFIC-4

724 enrolled

Carcinoma, Non-Small-Cell Lung, Lung Neoplasms

NCT06591520 2026-01-21

AK112 Combined With Chemotherapy Versus Durvalumab Combined With Chemotherapy in Advanced Biliary Tract Cancer

682 enrolled

Biliary Tract Neoplasms

NCT04592913 2025-12-24

Assessing Durvalumab and FLOT Chemotherapy in Resectable Gastric and Gastroesophageal Junction Cancer

957 enrolled 3 FDA

Gastrointestinal Neoplasms

NCT04269200 2025-12-23

DUO-E

805 enrolled 18 charts 2 FDA

Gynecologic

Endometrial Neoplasms

NCT06211036 2025-12-17

DeLLphi-305

563 enrolled

Small Cell Lung Carcinoma

NCT03703297 2025-11-21

ADRIATIC

730 enrolled 19 charts 3 FDA

Carcinoma, Lung Neoplasms, Small Cell Lung Carcinoma

NCT03519971 2025-10-28

Study of Durvalumab Given With Chemoradiation Therapy in Patients With Unresectable Non-small Cell Lung Cancer

328 enrolled 23 charts

Carcinoma, Carcinoma, Non-Small-Cell Lung

NCT03043872 2025-10-21

CASPIAN

987 enrolled 42 charts 3 FDA

Small Cell Lung Carcinoma

NCT04513925 2025-09-08

SKYSCRAPER-03

Phase 3 Completed

829 enrolled

Carcinoma, Non-Small-Cell Lung

NCT04380636 2025-08-17

MK-7339-012

870 enrolled

Parkinson Disease 4, Autosomal Dominant Lewy Body, Carcinoma, Non-Small-Cell Lung, Lung Neoplasms

NCT05298423 2025-08-01

KEYVIBE-006

611 enrolled

Parkinson Disease 4, Autosomal Dominant Lewy Body, Carcinoma, Non-Small-Cell Lung

NCT04026412 2025-07-24

CheckMate73L

Phase 3 Completed

925 enrolled 25 charts